



Avalanche Biotechnologies to Present at Upcoming Investor Conferences

February 25, 2015

MENLO PARK, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at three upcoming investor conferences:

- Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 9:20 a.m. EST in Boston.
- Barclays Global Healthcare Conference on Tuesday, March 10, 2015 at 2:50 p.m. EDT in Miami, FL.
- Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 2:25 p.m. EDT in New York.

Live webcasts of the Cowen and Company and Barclays presentations will be accessible under [Events & Presentations](#) in the Investors section of Avalanche's website. Avalanche will maintain an archived replay of the webcasts on its website for two weeks after each conference.

About Avalanche Biotechnologies, Inc.

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet age-related macular degeneration. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information, please visit www.avalanchebiotech.com.

CONTACT: Media and Investor Contact Susan Neath Francis (212) 301-7182 sfrancis@w2ogroup.com

[Avalanche Biotechnologies Logo](#)

Avalanche Biotechnologies, Inc.